MASS · 908 Devices Inc.
$12.51
+0.17 (+1.38%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$472.86M
Shares
41.33M
Volume · Oct 1
594.87K
Avg daily vol (3M)
388.04K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.34
Open$11.89
Day$11.83–12.47
52W close$5.09–12.34
Avg vol 30d417K
Short int2.7M · 6.6% float · 9.3d
Short vol65%
Last earningsAug 11, 2026
DataDec 2020–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 19, 2026
Est · unconfirmed
· in 7 wks
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+40.9%
Trailing year
Short interest
6.6%
Latest settlement · 9.3 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. 908 Devices posted 23% Q2 revenue growth to $16.1M, more than halved its adjusted EBITDA loss to negative $1.9M, and raised the low end of its 2026 revenue outlook to $68-70M, while reporting an $11.9M net loss from continuing operations and pulling AVCAD out of guidance.
Bullish
- + Q2 revenue grew 23% year-over-year to $16.1 million.
- + Adjusted EBITDA loss improved by more than 50% year-over-year to negative $1.9M.
- + Company raised the low end of 2026 revenue guidance to $68-70M (21-25% growth).
- + Adjusted gross margin expanded 85 basis points to 57% in Q2.
- + NearLab acquisition is ramping, with more than 35 devices sold in roughly two months post-close.
Bearish
- − Net loss from continuing operations was $11.9 million in Q2 2026.
- − AVCAD program contribution was removed from 2026 core guidance, with any contribution now upside-only.
- − Recurring revenue grew only 4% year-over-year to $4.9 million.
- − Q2 cash usage of $10.2 million included $13.5M for the NearLab acquisition.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+61%
above
Price vs 50-day avg
+26%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
100%
near high
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+77%
trailing
YTD return
+135%
this year
Relative strength
+65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +14 funds added
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Falling
6.65% of float · ▼ -2.2% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
111 holders — mid 3-yr range
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
+18%
Y/Y
Gross margin
51%
contracting
EPS growth
+125%
Y/Y
Free cash flow
$-24.6M
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 11, 2026
OEM and funded partnerships, including contract revenue
· full year 2026
Initiated
$3M
Guided vs delivered
· last 3 settled
Full year reported 2024 revenue
full year 2024
guided $63M – $65M
$47.75M
Miss −25.4%
Revenue
full year 2023
guided $49M – $51M
$50.23M
In line
Revenue
2021
guided $41M – $43M
$42.21M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+61%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +14 funds added
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Falling
6.65% of float · ▼ -2.2% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
111 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $12 · 100%
Range high $12
vs 200-day avg +61%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | -$4.45M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA loss non-GAAP | 1.9M | Q2 2026 | — |
| Adjusted Gross Margin Percentage (Non-GAAP) non-GAAP | 57% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit (Non-GAAP) non-GAAP | $16.86M | Six Months Ended June 30, 2026 | — |
| Devices placed | 198 | Q2 2026 | — |
| Installed base | 4,101 | Q2 2026 | — |
| Product Placements - Handheld | 198 | Three Months Ended June 30, 2026 filing | — |
| Recurring revenue | 4.9M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MASS
this stock
908 Devices Inc.
|
$472.86M | +135.0% | +17.7% | — | 6.6% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MASS | +12.8% | +15.9% | +77.3% | +15.7% | +135.1% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +13.5% | +15.8% | +65.1% | +16.2% | +123.2% |